Mosaic ImmunoEngineering Announces Exclusive Technology Licensing Agreement with Case Western Reserve University


The licensed technology was jointly invented by researchers at Case Western Reserve University and Dartmouth College

The license covers the use of plant viruses such as cowpea mosaic virus (CPMV) for the treatment of cancer in humans and pets.

NOVATO, CA/ACCESSWIRE/May 5, 2022/ Mosaic ImmunoEngineering, Inc. (“Mosaic” or the “Company”), (OTCQB: CPMV), a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer, today announced the signing of a license agreement with Case Western Reserve University for patented technology discovered at Case Western Reserve University and Dartmouth College. The agreement grants Mosaic exclusive worldwide rights to develop and commercialize oncology treatments based on cowpea mosaic virus (CPMV), the core technology behind the company’s lead human cancer immunotherapy candidate, MIE- 101, and other applications under the platform technology.

“In addition to providing world-class research in many areas, Case Western Reserve University and Dartmouth College are working to translate these exciting discoveries into products and therapies that can make a difference in the lives of patients with potentially life-threatening diseases. deadly,” said Wayne Hawthorne, Senior Licensing Manager at Case Western Reserve University. “We encourage our faculty to conduct basic research that can become the basis for discoveries that have direct application to clinical needs such as the technology Mosaic seeks to advance.”

“This licensed technology is an important part of our intellectual property portfolio, protecting the development of our lead CPMV-based immunotherapy, MIE-101, including treatments for humans and companion animals,” said Steven King. , President and CEO of Mosaic. . “We have noted recent activity in the area of ​​intra-tumor immunotherapy and believe that CPMV may offer distinct advantages over other approaches currently in development. MIE-101 is a first-in-class differentiated immunotherapy that is supported by numerous peer-reviewed publications, including data from both preclinical animal models and pets with spontaneous tumors.We look forward to providing updates as we continue to advance the program.

Under the license agreement, Mosaic will make development and regulatory milestone payments to Case Western Reserve University and will also pay tiered royalties on net sales of licensed products.

About MIE-101

Mosaic’s lead therapeutic candidate, MIE-101, is derived from cowpea mosaic virus (CPMV), a plant virus that does not infect humans or animals, but can stimulate both innate immune responses and adaptive, as shown in multiple preclinical cancer models, including melanoma, breast, ovary, brain, and colon. Unlike experimental intratumoral treatments intended to use viruses to directly invade and destroy cancer cells, known as oncolytic viruses, MIE-101 represents a unique approach to cancer treatment. MIE-101 has been shown to engage multiple pattern recognition receptors on tumor host immune cells that have evolved to detect foreign invaders. Preclinical studies have demonstrated that these immune cells then attack the tumor, while producing molecules that attract, activate, and train additional immune cells to recognize and fight the tumor that was directly treated as well as to attack tumors in other body regions. MIE-101 has demonstrated single-agent activity in preclinical tumor models and in canine companion animals with natural tumors. MIE-101 has also demonstrated enhanced antitumor effects when combined with immune checkpoint treatments and other standard cancer treatments.

About Mosaic ImmunoEngineering, Inc.

Mosaic ImmunoEngineering, Inc. is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. Mosaic’s core technology platform is based on cowpea mosaic virus (“CPMV”), which is not infective to humans or other animals but which, when administered intratumourally, elicits a strong innate immune response resulting in potent antitumor activity against primary and distant tumor sites. The broad potential of our lead candidate, MIE-101, for the treatment of many types of cancer and potential combination therapies continues to be supported by numerous publications and grants through our academic collaborators and co-founders of the UC San Diego Center for Nano-ImmunoEngineering. For more information about Mosaic, please visit

Forward-looking statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. For example, we use forward-looking statements when discussing Mosaic’s future operations and its ability to successfully advance product candidates; the nature, strategy and direction of Mosaic’s business; and the development, commercial potential and potential benefits of any Mosaic product candidate. Mosaic may not actually achieve the plans, achieve the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on such forward-looking statements. Because these statements address future events and are based on Mosaic’s current expectations, they are subject to various risks and uncertainties, and the actual results, performance or achievements of these forward-looking statements could differ materially from those described or implied. by statements in this press release, including uncertainties regarding: the raising of sufficient capital or grant funding to advance these product candidates, which may not be available on favorable terms or at all; maintain the rights to the licensed technology and comply with the underlying terms of the license agreement; advancing Mosaic’s lead product through clinical trials, clinical development and regulatory approval of Mosaic’s product candidates, including potential delays in start-up; enrollment and completion of clinical trials; the possibility that prior preclinical studies of Mosaic’s product candidates may not be predictive of future outcomes; risks related to business interruptions, including, but not limited to, the COVID-19 coronavirus outbreak, which could adversely affect Mosaic’s financial condition and increase its costs and expenses. The foregoing discussion of important factors that could cause actual events to differ from expectations should not be construed as complete and should be read in conjunction with the statements included herein and elsewhere, including the risks discussed in the filings by Mosaic with the Securities and Exchange Commission. Except as otherwise required by law, Mosaic disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

Jay Carlson
Senior Manager, Investor Relations
Mosaic ImmunoEngineering Inc.
[email protected]

Corporate strategic inquiries can be sent to [email protected]

THE SOURCE: Mosaic ImmunoEngineering Inc.

See the source version on


Comments are closed.